Columbia Labs Divesting OTC Lines To Focus On Rx Pipeline

Columbia Labs is seeking to divest the bulk of its OTC product lines in order to concentrate on its prescription drug pipeline. The company has engaged investment banking firm Ryan, Beck & Co. as its exclusive advisor in the process.